--- title: "Myriad Genetic | 10-K: FY2025 Revenue Beats Estimate at USD 824.5 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/276785584.md" datetime: "2026-02-24T21:04:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276785584.md) - [en](https://longbridge.com/en/news/276785584.md) - [zh-HK](https://longbridge.com/zh-HK/news/276785584.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/276785584.md) | [繁體中文](https://longbridge.com/zh-HK/news/276785584.md) # Myriad Genetic | 10-K: FY2025 Revenue Beats Estimate at USD 824.5 M Revenue: As of FY2025, the actual value is USD 824.5 M, beating the estimate of USD 822.69 M. EPS: As of FY2025, the actual value is USD -3.95. EBIT: As of FY2025, the actual value is USD -378.5 M. #### Overall Financial Performance - Myriad Genetics, Inc. reported a net loss of - $365.9 million in 2025, compared to a net loss of - $127.3 million in 2024. #### Revenue by Product Category - **Hereditary Cancer:** Revenue increased by 2% to $372.4 million in 2025 from $364.5 million in 2024. - **Tumor Profiling:** Revenue decreased by 3% to $121.7 million in 2025 from $125.8 million in 2024, primarily due to the divestment of the EndoPredict business in August 2024. - **Prenatal:** Revenue increased by 5% to $186.3 million in 2025 from $177.1 million in 2024. - **Mental Health:** Revenue decreased by 15% to $144.1 million in 2025 from $170.2 million in 2024, mainly due to a 20% decrease in average revenue per test following UnitedHealthcare’s policy change on GeneSight test coverage. #### Testing Volume by Product Category - Total testing volume increased by 1% to 1,537 thousand tests in 2025 from 1,520 thousand tests in 2024. - **Hereditary Cancer:** Volume increased by 7% to 315 thousand tests in 2025 from 294 thousand tests in 2024. - **Tumor Profiling:** Volume decreased by 9% to 48 thousand tests in 2025 from 53 thousand tests in 2024. - **Prenatal:** Volume decreased by 4% to 637 thousand tests in 2025 from 666 thousand tests in 2024, driven by a decline in SneakPeek volume. - **Mental Health:** Volume increased by 6% to 537 thousand tests in 2025 from 507 thousand tests in 2024. #### Revenue by Geographical Region - **U.S. Revenue:** $768.0 million in 2025 compared to $769.5 million in 2024. - **Rest of World (RoW) Revenue:** $56.5 million in 2025 compared to $68.1 million in 2024. #### Operating Expenses - **Cost of Revenue:** Decreased by - $4.3 million (-2%) to $247.9 million in 2025 from $252.2 million in 2024, maintaining 30.1% of total revenue in both years. - **Research and Development Expense:** Decreased by - $6.6 million (-6%) to $106.8 million in 2025 from $113.4 million in 2024, primarily due to lower compensation-related expenses. - **Sales and Marketing Expense:** Decreased by - $3.3 million (-1%) to $280.8 million in 2025 from $284.1 million in 2024. - **General and Administrative Expense:** Decreased by - $19.1 million (-7%) to $256.8 million in 2025 from $275.9 million in 2024, largely due to a - $9.8 million decrease in amortization for previously impaired intangible assets. - **Legal Settlements:** Zero in 2025, compared to - $21.3 million in 2024, which included a reversal of expense for a contingent payment related to the Ravgen settlement. - **Goodwill and Long-lived Asset Impairment Charges:** Increased significantly to $319.4 million in 2025 from $56.8 million in 2024. This included goodwill impairment charges of $234.7 million and intangible asset impairment charges of $82.0 million related to the Women’s Health and Mental Health reporting units in 2025. - **Other Expense, net:** Increased to - $7.9 million in 2025 from $0 million in 2024, mainly due to higher interest expense from the new term loan. #### Cash Flow - **Net cash provided by operating activities:** Increased to $1.8 million in 2025 from - $8.7 million in 2024, driven by changes in working capital. - **Net cash used in investing activities:** Increased to - $27.4 million in 2025 from - $11.9 million in 2024, as 2024 included cash inflows from investment maturities and the sale of the EndoPredict business. - **Net cash provided by financing activities:** Increased to $64.2 million in 2025 from - $7.4 million in 2024, primarily due to proceeds from the new Credit Facility, partially offset by repayment of the prior ABL Facility and debt issuance costs. #### Outlook / Guidance Myriad Genetics, Inc. expects to discontinue sales of its EndoPredict test in the United States during the first half of 2026. The company anticipates R&D investment to increase in 2026, with a focus on the Cancer Care Continuum. The change in UnitedHealthcare’s coverage for the GeneSight test is expected to continue negatively affecting Mental Health revenue in future periods. ### Related Stocks - [Myriad Genetics, Inc. (MYGN.US)](https://longbridge.com/en/quote/MYGN.US.md) ## Related News & Research - [Berenberg Lifts FY26 Estimates for Ferrari on Expected 'Strong' Q1](https://longbridge.com/en/news/281471058.md) - [KDDI Revises First-Half FY2025 IFRS Results but Confirms Earnings Growth](https://longbridge.com/en/news/281160478.md) - [Wealth First Promoters Confirm 74% Stake With No Encumbrance in FY26](https://longbridge.com/en/news/281530653.md) - [Dover Earnings Preview: What to Expect](https://longbridge.com/en/news/281167111.md) - [Cintas (CTAS) Valuation Check After Q3 Results And Higher Fiscal 2026 Guidance](https://longbridge.com/en/news/281225115.md)